A Review of Biomarkers for Neurodegenerative Disease: Will They Swing Us Across the Valley?

Abstract

Measures of the severity of cognitive impairment or parkinsonism are the usual endpoints in clinical trials for Alzheimer's disease (AD) and Parkinson's disease (PD), but are critically hampered by their lack of disease sensitivity and specificity. Due to the high failure rate of clinical trials, the rate of regulatory approval for efficacious new drugs has… (More)
DOI: 10.1007/s40120-017-0072-x

Topics

Cite this paper

@inproceedings{Beach2017ARO, title={A Review of Biomarkers for Neurodegenerative Disease: Will They Swing Us Across the Valley?}, author={Thomas Beach}, booktitle={Neurology and therapy}, year={2017} }